Treace Medical Concepts (TMCI)
NASDAQ:TMCI
Want to see TMCI full AI Analyst Report?
TMCI Stock Chart & Stats
$1.87
-$0.15(-1.96%)
At close: 4:00 PM EST
$1.87
-$0.15(-1.96%)
Day’s Range― - ―
52-Week Range$1.17 - $7.78
Previous CloseN/A
Volume76.56K
Average Volume (3M)918.48K
Market Cap
$144.04M
Enterprise Value$128.58M
Total Cash (Recent Filing)$48.37M
Total Debt (Recent Filing)$13.98M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
May 13, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding64,590,500
10 Day Avg. Volume1,009,218
30 Day Avg. Volume918,480
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)1.77
Price to Sales (P/S)0.73
P/FCF Ratio-5.26
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue0.60
Enterprise Value/Gross Profit0.76
Enterprise Value/Ebitda-2.99
Forecast
1Y Price Target
$4.08Price Target Upside118.18% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.91
Revenue Forecast (FY)$205.69M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~80% gross margins indicate durable product-level economics from implants and instrumentation. High unit margins give the company strong operating leverage as volumes recover and support a clearer path to sustained profitability once fixed SG&A scales down or revenue stabilizes.
Product Portfolio Expansion And TAM GrowthMultiple new systems plus planned launches materially enlarge the addressable market and diversify revenue streams. Combined with surgeon adoption growth (from ~1,300 to over 3,300 since 2020), this widens the long-term revenue runway and reduces dependence on a single product line.
Improving Liquidity And Lower LeverageStronger liquidity and a sizable credit facility, paired with materially reduced debt, provide runway to fund product rollouts and absorb near-term cash burn. Lower leverage reduces refinancing risk and interest burden, improving financial flexibility during commercialization.
Bears Say
Persistent Operating Losses And Negative Cash FlowThe company continues to produce meaningful operating losses and negative free cash flow, requiring external funding. Until operations generate positive cash flow, Treace will face constraints on self-funding growth initiatives and remain exposed to financing availability and cost.
Stalled Revenue Growth And Weak 2026 GuidanceManagement's flat-to-declining revenue outlook limits operating leverage and delays margin expansion from high gross margins. Stagnant top-line performance reduces return on recent R&D and sales investments and makes reaching sustained profitability more dependent on successful new-product adoption.
Product Mix Pressure And Market SoftnessA structural shift toward lower-ASP products and softness in elective foot-and-ankle procedures compresses revenue per case and slows dollar growth even if procedure counts rise. Recovery hinges on adoption of higher-ASP launches, which could take multiple quarters to meaningfully change revenue mix.
Treace Medical Concepts News
TMCI FAQ
What was Treace Medical Concepts’s price range in the past 12 months?
Treace Medical Concepts lowest stock price was $1.17 and its highest was $7.78 in the past 12 months.
What is Treace Medical Concepts’s market cap?
Treace Medical Concepts’s market cap is $144.04M.
When is Treace Medical Concepts’s upcoming earnings report date?
Treace Medical Concepts’s upcoming earnings report date is May 13, 2026 which is in 25 days.
How were Treace Medical Concepts’s earnings last quarter?
Treace Medical Concepts released its earnings results on Feb 27, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.152 by $0.002.
Is Treace Medical Concepts overvalued?
According to Wall Street analysts Treace Medical Concepts’s price is currently Undervalued.
Does Treace Medical Concepts pay dividends?
Treace Medical Concepts does not currently pay dividends.
What is Treace Medical Concepts’s EPS estimate?
Treace Medical Concepts’s EPS estimate is -0.31.
How many shares outstanding does Treace Medical Concepts have?
Treace Medical Concepts has 64,590,500 shares outstanding.
What happened to Treace Medical Concepts’s price movement after its last earnings report?
Treace Medical Concepts reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.152. Following the earnings report the stock price went down -11.429%.
Which hedge fund is a major shareholder of Treace Medical Concepts?
Currently, no hedge funds are holding shares in TMCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Treace Medical Concepts Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.08 (118.18% Upside)
$4.08 (118.18% Upside)
Hedge Fund Trend
Increased
By 120.7K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.80%
12-Months-Change
Fundamentals
Return on Equity
-51.63%
Trailing 12-Months
Asset Growth
-7.67%
Trailing 12-Months
Company Description
Treace Medical Concepts
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
TMCI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: the company demonstrated meaningful operational progress — expanding its product portfolio, accelerating surgeon adoption, materially reducing cash burn and improving full-year adjusted EBITDA vs prior year — and secured liquidity. However, these positives are offset by near-term revenue pressure driven by a mix shift toward lower-priced products, market softness in elective foot and ankle procedures, a sizable Q4 GAAP net loss increase, and guidance that implies flat-to-declining revenue for 2026 with an expectation of an adjusted EBITDA loss. Management expects improvements later in 2026 (stronger Q3/Q4) as new higher-ASP products launch and adoption deepens, but the current outlook and recent quarterly results temper the outlook.View all TMCI earnings summariesTMCI Stock 12 Month Forecast
Average Price Target
$4.08
▲(118.18% Upside)
Technical Analysis
Ownership Overview
29.16% Insiders
8.91% Mutual Funds
24.97% Other Institutional Investors
29.53% Public Companies and
Individual Investors